Successful in vivo propagation of factor IX-producing hepatocytes in mice: Potential for cell-based therapy in haemophilia B

Thrombosis and Haemostasis

Volumn 99, Issue 5, 2008, Pages 883-891

  Tatsumi, Kohei ^a   Ohashi, Kazuo ^a,d   Kataoka, Miho ^b   Tateno, Chise ^b,e   Shibata, Masaru ^a   Naka, Hiroyuki ^a   Shima, Midori ^a   Hisanaga, Michiyoshi ^a   Kanehiro, Hiromichi ^a   Okano, Teruo ^d   Yoshizato, Katsutoshi ^b,c,e   Nakajima, Yoshiyuki ^a   Yoshioka, Akira ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b Hiroshima Prefectural Univ   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

^d TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^e PhoenixBio USA Corporation   (Japan)

Author keywords

Coagulation factors; Haemophilia A B; Haemophilia therapy; Hepatology

Indexed keywords

BLOOD CLOTTING FACTOR 9; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL FUNCTION; CELL PROLIFERATION; CELL THERAPY; CONTROLLED STUDY; HEMOPHILIA B; IN VIVO STUDY; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE;

ANIMALS; CELL CULTURE TECHNIQUES; CELL PROLIFERATION; CELL TRANSPLANTATION; CELLS, CULTURED; CHILD; DOGS; FACTOR IX; FEMALE; HEMOPHILIA B; HEPATOCYTES; HUMANS; INFANT; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, SCID; MICE, TRANSGENIC; RNA, MESSENGER; SERUM ALBUMIN; TIME FACTORS; TRANSPLANTATION, HETEROLOGOUS; URINARY PLASMINOGEN ACTIVATOR;

EID: 43949111304     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-09-0559     Document Type: Article

References (50)

1. Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet 2003; 361: 1801-1809.
2. Hsu TC, Nakaya SM, Thompson AR. Severe haemophilia B due to a 6 kb factor IX gene deletion including exon 4: non-homologous recombination associated with a shortened transcript from whole blood. Thromb Haemost 2007; 97: 176-180.
3. Nathwani AC, Davidoff AM, Tuddenham EG. Prospects for gene therapy of haemophilia. Haemophilia 2004; 10: 309-318.
4. Ehrhardt A, Kay MA. A new adenoviral helper-dependent vector results in long-term therapeutic levels of human coagulation factor IX at low doses in vivo. Blood 2002; 99: 3923-3930.
5. Herzog RW, Yang EY, Couto LB, et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med 1999; 5: 56-63.
6. Kay MA, Rothenberg S, Landen CN, et al. In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs. Science 1993; 262: 117-119.
7. Miao CH, Thompson AR, Loeb K, et al. Long-term and therapeutic-level hepatic gene expression of human factor IX after naked plasmid transfer in vivo. Mol Ther 2001; 3: 947-957.
8. Mount JD, Herzog RW, Tillson DM, et al. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood 2002; 99: 2670-2676.
9. Nathwani AC, Davidoff A, Hanawa H, et al. Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA. Blood 2001; 97: 1258-1265.
10. Park F, Ohashi K, Kay MA. Therapeutic levels of human factor VIII and IX using HIV-1-based lentiviral vectors in mouse liver. Blood 2000; 96: 1173-1176.
11. Xu L, Gao C, Sands MS, et al. Neonatal or hepatocyte growth factor-potentiated adult gene therapy with a retroviral vector results in therapeutic levels of canine factor IX for hemophilia B. Blood 2003; 101: 3924-3932.
12. Yant SR, Meuse L, Chiu W, et al. Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system. Nat Genet 2000; 25: 35-41.
13. Manno CS, Chew AJ, Hutchison S, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 2003; 101: 2963-2972.
14. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006; 12: 342-347.
15. Bontempo FA, Lewis JH, Gorenc TJ, et al. Liver transplantation in hemophilia A. Blood 1987; 69: 1721-1724.
16. Ko S, Tanaka I, Kanehiro H, et al. Preclinical experiment of auxiliary partial orthotopic liver transplantation as a curative treatment for hemophilia. Liver Transpl 2005; 11: 579-584.
17. Merion RM, Delius RE, Campbell DA, Jr., et al. Orthotopic liver transplantation totally corrects factor IX deficiency in hemophilia B. Surgery 1988; 104: 929-931.
18. Boost KA, Auth MK, Woitaschek D, et al. Long-term production of major coagulation factors and inhibitors by primary human hepatocytes in vitro: perspectives for clinical application. Liver Int 2007; 27: 832-844.
19. Greenberg D, Miao CH, Ho WT, et al. Liver-specific expression of the human factor VII gene. Proc Natl Acad Sci USA 1995; 92: 12347-12351.
20. Hjortoe G, Sorensen BB, Petersen LC, et al. Factor VIIa binding and internalization in hepatocytes. J Thromb Haemost 2005; 3: 2264-2273.
21. Hollestelle MJ, Thinnes T, Crain K, et al. Tissue distribution of factor VIII gene expression in vivo - a closer look. Thromb Haemost 2001; 86: 855-861.
22. Kelly DA, Summerfield JA, Tuddenham EG. Localization of factor VIIIC: antigen in guinea-pig tissues and isolated liver cell fractions. Br J Haematol 1984; 56: 535-543.
23. Rodriguez-Inigo E, Bartolome J, Quiroga JA, et al. Expression of factor VII in the liver of patients with liver disease: correlations with the disease severity and impairment in the hemostasis. Blood Coagul Fibrinolysis 2001; 12: 193-199.
24. Wion KL, Kelly D, Summerfield JA, et al. Distribution of factor VIII mRNA and antigen in human liver and other tissues. Nature 1985; 317: 726-729.
25. Ohashi K, Kay MA, Kuge H, et al. Heterotopically transplanted hepatocyte survival depends on extracellular matrix components. Transplant Proc 2005; 37: 4587-4588.
26. Ohashi K, Kay MA, Yokoyama T, et al. Stability and repeat regeneration potential of the engineered liver tissues under the kidney capsule in mice. Cell Transplant 2005; 14: 621-627.
27. Ohashi K, Marion PL, Nakai H, et al. Sustained survival of human hepatocytes in mice: A model for in vivo infection with human hepatitis B and hepatitis delta viruses. Nat Med 2000; 6: 327-331.
28. Ohashi K, Waugh JM, Dake MD, et al. Liver tissue engineering at extrahepatic sites in mice as a potential new therapy for genetic liver diseases. Hepatology 2005; 41: 132-140.
29. Ohashi K, Yokoyama T, Yamato M, et al. Engineering functional two- and three-dimensional liver systems in vivo using hepatic tissue sheets. Nat Med 2007; 13: 880-885.
30. Yokoyama T, Ohashi K, Kuge H, et al. In vivo engineering of metabolically active hepatic tissues in a neovascularized subcutaneous cavity. Am J Transplant 2006; 6: 50-59.
31. Dhawan A, Mitry RR, Hughes RD, et al. Hepatocyte transplantation for inherited factor VII deficiency. Transplantation 2004; 78: 1812-1814.
32. Ostrowska A, Bode DC, Pruss J, et al. Investigation of functional and morphological integrity of freshly isolated and cryopreserved human hepatocytes. Cell Tissue Bank 2000; 1: 55-68.
33. Ohashi K, Park F, Kay MA. Hepatocyte transplantation: clinical and experimental application. J Mol Med 2001; 79: 617-630.
34. Kobayashi N, Fujiwara T, Westerman KA, et al. Prevention of acute liver failure in rats with reversibly immortalized human hepatocytes. Science 2000; 287: 1258-1262.
35. Tateno C, Yoshizane Y, Saito N, et al. Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 2004; 165: 901-912.
36. Hamatani K, Matsuda Y, Araki R, et al. Cloning and chromosomal mapping of the mouse DNA-dependent protein kinase gene. Immunogenetics 1996; 45: 1-5.
37. Emoto K, Tateno C, Hino H, et al. Efficient in vivo xenogeneic retroviral vector-mediated gene transduction into human hepatocytes. Hum Gene Ther 2005; 16: 1168-1174.
38. Yoshitsugu H, Nishimura M, Tateno C, et al. Evaluation of human CYP1A2 and CYP3A4 mRNA expression in hepatocytes from chimeric mice with humanized liver. Drug Metab Pharmacokinet 2006; 21: 465-474.
39. Greene AK, Puder M. Partial hepatectomy in the mouse: technique and perioperative management. J Invest Surg 2003; 16: 99-102.
40. Ito Y, Hayashi H, Taira M, et al. Depression of liver-specific gene expression in regenerating rat liver: a putative cause for liver dysfunction after hepatectomy. J Surg Res 1991; 51: 143-147.
41. Kurumiya Y, Nozawa K, Sakaguchi K, et al. Differential suppression of liver-specific genes in regenerating rat liver induced by extended hepatectomy. J Hepatol 2000; 32: 636-644.
42. Rawle FE, Lillicrap D. Preclinical animal models for hemophilia gene therapy: predictive value and limitations. Semin Thromb Hemost 2004; 30: 205-213.
43. Fisher RA, Strom SC. Human hepatocyte transplantation: worldwide results. Transplantation 2006; 82: 441-449.
44. Huth-Kuhne A, Rott H, Zimmermann R, et al. Recombinant factor VIIa for long-term replacement therapy in patients with congenital factor VII deficiency. Thromb Haemost 2007; 98: 912-915.
45. Rosenthal C, Volk T, Spies C, et al. Successful coronary artery bypass graft surgery in severe congenital factor VII deficiency: perioperative treatment with factor VII concentrate. Thromb Haemost 2007; 98: 900-902.
46. Arruda VR, Hagstrom JN, Deitch J, et al. Posttranslational modifications of recombinant myotube-synthesized human factor IX. Blood 2001; 97: 130-138.
47. Masumoto N, Tateno C, Tachibana A, et al. GH enhances proliferation of human hepatocytes grafted into immunodeficient mice with damaged liver. J Endocrinol 2007; 194: 529-537.
48. Walldorf J, Aurich H, Cai H, et al. Expanding hepatocytes in vitro before cell transplantation: donor age-dependent proliferative capacity of cultured human hepatocytes. Scand J Gastroenterol 2004; 39: 584-593.
49. Azuma H, Paulk N, Ranade A, et al. Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/-mice. Nat Biotechnol 2007; 25: 903-910.
50. Slehria S, Rajvanshi P, Ito Y, et al. Hepatic sinusoidal vasodilators improve transplanted cell engraftment and ameliorate microcirculatory perturbations in the liver. Hepatology 2002; 35: 1320-1328.